Robert Wasserman Analyst PerformanceSenior Research Analyst at BenchmarkRobert Wasserman is a stock analyst at Benchmark focused in the medical sector, covering 16 publicly traded companies. Over the past year, Robert Wasserman has issued 13 stock ratings, including buy and hold recommendations. While full access to Robert Wasserman's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Robert Wasserman's coverage history, rating activity, and performance tendencies - helping individual investors make more informed trading decisions. Analyst Rankings, Coverage, and Performance StatisticsAnalyst RankingSubscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeatAverage Return00.00% 12-Month ROISuccess Rate00.00% Profitable RatingsTotal Ratings30 Last 7 YearsBuy Recommendations90.00% 27 Buy RatingsCompanies Covered16 Unique Companies Ratings Distribution30RatingsDistribution of strong buy, buy, hold, and sell ratings by Robert Wasserman.RatingPercentageCount Strong Buy0.0%0 ratings Buy90.0%27 ratings Hold10.0%3 ratings Sell0.0%0 ratingsOut of 30 total stock ratings issued by Robert Wasserman at Benchmark, the majority (90.0%) have been Buy recommendations, followed by 10.0% Hold.Best & Worst CallsBest Call000.0%XOMAApr 2025Subscribe to MarketBeat All Access to get analyst recommendation ROI.Worst Call000.0%IDXGOct 2018Subscribe to MarketBeat All Access to get analyst recommendation ROI.Exchange CoverageExchangePercentageCountNASDAQ75.0% of companies on NASDAQ12 companiesNYSE18.8% of companies on NYSE3 companiesOTCMKTS6.3% of companies on OTCMKTS1 companyRobert Wasserman, an analyst at Benchmark, currently covers 16 companies listed on NASDAQ, NYSE and OTCMKTS, with the majority traded on NASDAQ.Coverage FocusSector IconSectorPercentageMedical15 companies93.8%Industrials1 company6.3%Robert Wasserman of Benchmark specializes in stock coverage within the Medical sector, with additional focus on Industrials companies.Coverage IndustriesIndustryPercentageMED - BIOMED/GENE9 companies56.3%MED INSTRUMENTS2 companies12.5%MED - DRUGS2 companies12.5%RUBBER&PLASTICS1 company6.3%MEDICAL INFO SYS1 company6.3%SURGICAL & MEDICAL INSTRUMENTS1 company6.3% About Robert WassermanRobert Wasserman is an Equity Research Analyst covering Bioprocessing and Life Sciences companies. Prior to Benchmark, Bob’s 25-plus years of investment experience includes previous equity research positions at Craig-Hallum, Dawson James, Southeast Research Partners, and Jesup & Lamont. He was named an All-Star Analyst in Healthcare by the Wall Street Journal and has been quoted and appeared in financial print and media outlets. Bob holds BS degrees in engineering and management from MIT and an MBA from the University of Chicago.Follow on LinkedIn Robert Wasserman's Ratings History at Benchmark Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe Start Date End Date All Ratings Strong Buy Buy Hold Sell Rating Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.Available with a MarketBeat All Access Subscription12-Month ROIUpgrade to All Access to use the All ROI Filter Export CompanyReport DateActionReport Date Price12-MonthPrice TargetRating12-MonthPrice & ROIDetailsRGENRepligen7/7/2026Upgrade$141.46$185.00Buy$0.0000.00% ROIABCLAbCellera Biologics7/7/2026Upgrade$7.87$11.00Buy$0.0000.00% ROIREGNRegeneron Pharmaceuticals7/7/2026Upgrade$649.81$185.00Buy$0.0000.00% ROIPRLBProto Labs7/2/2026Boost Price Target$76.61$91.00Buy$0.0000.00% ROITECHBio-Techne6/30/2026Downgrade$70.90Hold$0.0000.00% ROIHALOHalozyme Therapeutics2/19/2026Boost Price Target$71.47$90.00Buy$0.0000.00% ROIHALOHalozyme Therapeutics2/3/2026Reiterated Rating$75.97Buy$0.0000.00% ROILGNDLigand Pharmaceuticals11/7/2025Boost Price Target$202.71$220.00Buy$0.0000.00% ROIPRLBProto Labs11/3/2025Boost Price Target$49.69$55.00Buy$0.0000.00% ROIITGRInteger10/24/2025Reiterated Rating$73.37Hold$0.0000.00% ROIHALOHalozyme Therapeutics9/24/2025Boost Price Target$77.57$90.00Buy$0.0000.00% ROILGNDLigand Pharmaceuticals9/2/2025Boost Price Target$163.94$175.00Buy$0.0000.00% ROIINTSIntensity Therapeutics8/20/2025Lower Price Target$7.48$37.50Speculative Buy$0.0000.00% ROITECHBio-Techne6/5/2025Reiterated Rating$49.10$75.00Buy$00.0000.00% ROIOABIOmniAb5/12/2025Reiterated Rating$1.47$6.00Buy$0.0000.00% ROITECHBio-Techne5/8/2025Lower Price Target$48.76$75.00Buy$00.0000.00% ROIITGRInteger4/25/2025Lower Price Target$120.27$140.00Buy$00.0000.00% ROIXOMAXOMA Royalty4/17/2025Initiated Coverage$20.53$35.00Buy$00.0000.00% ROIIPAImmunoPrecise Antibodies4/1/2025Reiterated Rating$0.36$3.00Speculative Buy$0.0000.00% ROIKMDAKamada3/21/2025Initiated Coverage$6.65$15.00Buy$0.0000.00% ROIOABIOmniAb3/20/2025Lower Price Target$2.45$6.00Buy$0.0000.00% ROIABCLAbCellera Biologics3/3/2025Reiterated Rating$2.50Hold$0.0000.00% ROIITGRInteger2/21/2025Boost Price Target$129.11$150.00Buy$00.0000.00% ROIHALOHalozyme Therapeutics2/20/2025Reiterated Rating$57.17$75.00Buy$00.0000.00% ROI Stock Forecasts and Research Tools Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Top Stock Recommendations by BrokerageUBS GroupCitigroupBarclaysRoyal Bank Of CanadaMorgan StanleyWells Fargo & CompanyJPMorgan Chase & Co.Jefferies Financial GroupThe Goldman Sachs GroupTD CowenTruist FinancialPiper SandlerBMO Capital MarketsDeutsche Bank AktiengesellschaftStifel Nicolaus Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
